Episurf Medical brings forward interim report

Due to the extraordinary general meeting that Episurf Medical AB today has summoned, Episurf Medical AB will bring forward its reporting date for the second quarter 2016 to August 10, 2016, 08.30 CET.

For more information, please contact:

Pål Ryfors, CFO, Episurf Medical

Tel: +46 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.40 CET on 26 July 2016.